关于激酶抑制剂的当代趋势,特别提到昆素衍生物
Kirti Sharma1, Asim Kumar2, Srikant Bhagat3
1Saraswati Institute of Pharmaceutical Education and Research, Gharuan, Mohali, 140413, Punjab, India.
Molecular diversity
|December 19, 2025
概括
昆素衍生物通过抑制酶来显示出具有前途的抗癌药物. 本综述强调了这些含异环的结构修改和作用机制.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 含的异环对于开发新型生物活性分子至关重要.
- 昆素是一种化和酸环系统,具有多种生物活性.
- 这些活动包括抗癌,抗微生物,抗结核,抗病毒,抗疹和肝脏保护作用.
研究的目的:
- 审查酶抑制剂作用方面的进展.
- 专注于从2009年到2024年报告的基于昆素的小分子激酶抑制剂.
- 强调抗癌药物开发的新兴作用机制和结构修改.
主要方法:
- 2009年至2024年科学报告的文献综述.
- 对昆素脚手架上的结构变化的分析.
- 检查激酶抑制活性和作用机制.
主要成果:
- 昆素支架是开发新型激酶抑制剂的组成部分.
- 各种结构修改增强了昆素衍生物的抗癌潜力.
- 详细介绍了这些抑制剂的新兴作用机制.
结论:
- 基于昆素的激酶抑制剂代表了抗癌药物发现的重要领域.
- 对结构修饰的进一步研究可以产生强效和选择性的抗癌剂.
- 了解详细的作用机制是优化治疗疗效的关键.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K


